IP02: Bladder Cancer: Non-invasive I
Friday, May 15, 2026 7:00 AM to 9:00 AM · 2 hr. (America/New_York)
146A
Poster and Podium Sessions
Oncology: Bladder
Friday, May 15
IP02-01: Metabolomics analysis identifies serum biomarkers predicting risk of intravesical tumorrecurrence after intravesical Bacillus Calmette–Guérin therapy (BCG) in patients withnon-muscle invasive bladder cancer
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-02: Dynamic Prediction of Recurrence and Progression Risk in Non-Muscle Invasive Bladder Cancer Using Conditional Survival: A SEER-Medicare Analysis
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-03: Prospective Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Sustained-Release Gemcitabine Docetaxel combination (NDV-01) in High-Risk NMIBC: Update with 9-month Complete Response Data
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-04: ADVANCED-2 (Cohort A): Preliminary Efficacy and Safety Data in BCG-Naïve Participants With High-Grade Non-Muscle Invasive Bladder Cancer
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-05: Cost-Effectiveness Analysis of Sasanlimab plus BCG for High-Risk Non-muscle Invasive Bladder Cancer (NMIBC): Analysis From CREST
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-06: Prognostic Outcomes Comparing Upfront Radical Cystectomy and Primary BCG Therapy in Very-High Risk Non-Muscle Invasive Bladder Cancer: An Updated Analysis in the Modern BCG Era
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-07: Holmium Laser En Bloc Resection vs Monopolar TURBT for Bladder Tumors >3 cm: A Prospective Randomized Trial—Interim Analysis
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-08: Efficacy of Nadofaragene firadenovec in Doubly Resistant Patients: A Real World Case Series
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-09: Development and Validation of a Urinary Extracellular Vesicle miRNA-Pair Model for the Non-Invasive Diagnosis of Urothelial Carcinoma
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
Yucai Wu
IP02-10: Macrophage-encapsulated Engineered EcN Expressing IL-15&IL-15Ra Fusion Protein Enhances Therapeutic efficacy in Intravesical Therapy
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-11: Predicting Cancer-Specific Mortality in Non-Muscle-Invasive Bladder Cancer: Comparative Performance of AUA vs EAU Risk Classifications
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-12: Risk Stratification of Ta High-Grade Non–Muscle Invasive Bladder Cancer: Insights from a Multicenter Cohort Study
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-14: Therapy-Induced Tertiary Lymphoid Structures in the Tumor Microenvironment Reflect Immune Reprogramming After Intravesical Bacillus Calmette-Guerin for non-muscle invasive bladder cancer
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-15: BCG therapy reshapes the urinary microbiome and immune cell landscape in non–muscle-invasive bladder cancer
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-16: Single-Center Prospective Study of Transurethral Gas-Bladder Ultrasonic Scalpel Bladder Tumor Resection: A Report on Technical Feasibility and Preliminary Efficacy
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-17: A Randomized Multicenter Crossover Study to Evaluate Patient Preference and Satisfaction with Urine-Based Molecular Testing versus Cystoscopy for Surveillance of Non-Muscle-Invasive Bladder Cancer (NMIBC)
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-18: Impact of chronic kidney disease on prognosis in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-19: Prognostic significance of symptom-driven recurrence in high-risk non-muscle-invasive bladder cancer
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-20: Immune Microenvironment Signatures of Response to Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-21: Longitudinal Quality of Life After Radical Cystectomy: A Comparative Analysis of Overall Trends between muscle-invasive versus non-muscle-invasive bladder cancer.
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
Rocco Simone Flammia
IP02-22: Survival Outcomes of BCG only, BCG plus EMDA-MMC, or Upfront Radical Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A Multicentre Collaborative Study from Two Independent Tertiary Referral Institutions
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-23: Duration of response to UGN-102 by age at baseline across 3 clinical trials in patients with low-grade intermediate-risk bladder cancer
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-24: Patient Experiences and Preferences for Chemoablation and Intravesical Drug-Releasing Systems in Non-Muscle-Invasive Bladder Cancer — A Mixed-Methods Study
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-25: Predictors of Disease Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer Following En Bloc Resection of Bladder Tumour
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-26: Development of a Non-Muscle Invasive Bladder Cancer (NMIBC) Genomic Score (NGS) that Outperforms Clinical Parameters to Predict Early BCG Failure
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-28: AI-informed Quantitative Mitosis Index Predicts BCG Maintenance Therapy benefit in High-Risk Non–Muscle-Invasive Bladder Cancer
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-27: Safety and Technical Feasibility Outcomes of En Bloc Resection of Bladder Tumour: First Analysis from The Global ERBT Registry
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-29: Reduced versus full dose BCG maintenance in NMIBC patients treated with full dose induction: A matched analysis
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
IP02-30: Development of a Machine Learning-Driven, Nanoscale Imaging Platform for Non-invasive Bladder Cancer Diagnosis in a Prospective, Cross-sectional, Case-Controlled Study
Friday, May 15, 2026 7:00 AM to 9:00 AM
146A
